Amgen profit tops Street expectations; focus on new drugs

Amgen, the world's biggest biotechnology company, also announced another positive result from a late-stage study of its high-profile experimental cholesterol drug, evolocumab. Amgen often adjusts its full-year forecasts over the course of the year. Analysts on average are looking for $ 8.18 per share and revenue of $ 19.57 billion, according to Thomson Reuters I/B/E/S. Excluding items, Amgen said …
world drug news – Yahoo News Search Results

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us